Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.
about
Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experienceDevelopment and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.Characterization of coding synonymous and non-synonymous variants in ADAMTS13 using ex vivo and in silico approachesThrombotic Thrombocytopenic Purpura in Black People: Impact of Ethnicity on Survival and Genetic Risk FactorsThrombotic thrombocytopenic purpura possibly triggered by Graves' disease.Thrombotic microangiopathies
P2860
Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.
@ast
Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.
@en
type
label
Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.
@ast
Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.
@en
prefLabel
Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.
@ast
Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.
@en
P2860
P356
P1476
Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura
@en
P2093
Massimo Franchini
Pier Mannuccio Mannucci
P2860
P304
P356
10.2450/2008.0056-07
P577
2008-07-01T00:00:00Z